Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | Journal Article | ||||||||||||
PMID | (30429128) | ||||||||||||
Authors | |||||||||||||
Title | Capivasertib Active against AKT1-Mutated Cancers. | ||||||||||||
|
|||||||||||||
URL | |||||||||||||
Abstract Text | The experimental pan-AKT inhibitor capivasertib (AZD5363) helped stabilize or shrink tumor growth in most patients with metastatic AKT1-mutant tumors enrolled in the U.S.-wide NCI-MATCH trial, according to data presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|